![]() |
CrossRef Text and Data Mining |
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
Radiation Response Modulation of GW572016 (EGFR/HER2 Dual Tyrosine Kinase Inhibitor) in Human Breast Cancer Xenografts |
Yeon Sil Kim, Kwang Won Roh, Soo Min Chae, Seong Kwon Mun, Sei Chul Yoon, Hong Seok Jang, Su Mi Chung |
Radiation Oncology Journal. 2007;25(4):233-241. |
Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance 554 POSTER The mTOR effector p70 S6 kinase 1 (S6K1): a specific biomarker for the biological effects of the dual HER1/HER2 kinase inhibitor Lapatinib (GW572016) in HER2-overexpressing breast cancer cells 194. Combining the Dual Tyrosine Kinase Inhibitor, Lapatinib, with HER2 Specific Cytotoxic T-Lymphocytes in the Treatment of HER2 Overexpressing Breast Cancer Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima®) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts Dual HER-2/EGFR tyrosine kinase inhibitors Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor Tyrosine kinase signalling in breast cancer: Modulation of tyrosine kinase signalling in human breast cancer through altered expression of signalling intermediates Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+breast cancer 567 POSTER Efficacy of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in combination with cytotoxic agents Antitumor activity of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (‘lressa’), alone or combined with gemcitabine and vinorelbine platinum-based chemotherapy, in human non-small-cell lung cancer (NSCLC) xenografts |
This metadata service is kindly provided by CrossRef from May 29, 2014. Radiat Oncol J has participated in CrossRef Text and Data Mining service since October 29, 2014. |